UK biotech financing update: March 2022 - May 2022

4 July 2022

The UK biotech sector has continued to attract investment despite global economic headwinds impacting all sectors, new data published by the UK BioIndustry Association (BIA) and Clarivate shows.

The data has been published as biotech leaders visit the Houses of Parliament to press policy makers to make the most of the UK’s competitive advantage to be at the forefront of global innovation in the 21st Century.

The new data on equity investment in the UK biotech and life sciences sector between March and May 2022 shows £450 million was raised, compared to £481 million in the first quarter of 2022. This included:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK